Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Fiedler

Showing results (71-80 of 195) with videos related to

Pageof 20
Sort By:
Frontiers in Medicine|November 25, 2021
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and MyelomaFranziska Brauneck, Pauline Weimer, Julian Schulze Zur Wiesch, et al.
International Journal of Molecular Sciences|December 10, 2021
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AMLFranziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2005
Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)Eckart Laack, Antje Scheffler, Iris Burkholder, et al.
Blood|February 13, 2008
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315IArtur Gontarewicz, Stefan Balabanov, Gunhild Keller, et al.
ESMO Open|July 19, 2018
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumoursWalter Fiedler, Herbert Stoeger, Antonella Perotti, et al.
Cancers|November 14, 2019
The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid LeukemiaArne Velthaus, Kerstin Cornils, Jan K Hennigs, et al.
Cancers|November 27, 2024
Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)Martin Schönrock, Piet Sonnemann, Nina Michalowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasisSonja Loges, Henning Clausen, Uta Reichelt, et al.
Oncoimmunology|November 20, 2019
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancerHauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2005
Long-term observation reveals time-course-dependent characteristics of tumour vascularisationNils Hansen-Algenstaedt, Claudia Joscheck, Christian Schaefer, et al.
Pageof 20

Showing results (71-80 of 195) with videos related to

Sort By:
Pageof 20
Frontiers in Medicine|November 25, 2021
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and MyelomaFranziska Brauneck, Pauline Weimer, Julian Schulze Zur Wiesch, et al.
International Journal of Molecular Sciences|December 10, 2021
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AMLFranziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2005
Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)Eckart Laack, Antje Scheffler, Iris Burkholder, et al.
Blood|February 13, 2008
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315IArtur Gontarewicz, Stefan Balabanov, Gunhild Keller, et al.
ESMO Open|July 19, 2018
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumoursWalter Fiedler, Herbert Stoeger, Antonella Perotti, et al.
Cancers|November 14, 2019
The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid LeukemiaArne Velthaus, Kerstin Cornils, Jan K Hennigs, et al.
Cancers|November 27, 2024
Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)Martin Schönrock, Piet Sonnemann, Nina Michalowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasisSonja Loges, Henning Clausen, Uta Reichelt, et al.
Oncoimmunology|November 20, 2019
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancerHauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2005
Long-term observation reveals time-course-dependent characteristics of tumour vascularisationNils Hansen-Algenstaedt, Claudia Joscheck, Christian Schaefer, et al.
Pageof 20